Why Roivant Sciences Ltd.’s (ROIV) Stock Is Up 9.20%
As of Wednesday, May 20, Roivant Sciences Ltd.’s ROIV share price has surged by 9.20%, which has investors questioning if this is right time to sell.Rosalio Madrigal
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Roivant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines and technologies. Its clinical product candidates include IMVT-1402, a fully human monoclonal antibody targeting FcRn in development across several IgG-mediated autoimmune indications; mosliciguat, an inhaled sGC activator in development for pulmonary hypertension associated with interstitial lung disease; neonatal fragment crystallizable receptor for the treatment of graves’ disease, difficult-to-treat rheumatoid arthritis, sjögren’s disease, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and cutaneous lupus erythematosus indications; batoclimab, a fully human monoclonal antibody for the treatment of thyroid eye disease; and brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis, non-infectious uveitis, cutaneous sarcoidosis, and other immune-mediated diseases. The company’s lead program consists of mosliciguat, an inhaled sGC activator for the treatment of pulmonary hypertension associated with interstitial lung disease and other cardiopulmonary diseases. In addition, the company offers delivery platforms comprising a lipid nanoparticle (LNP) platform and a ligand conjugate platform. Roivant Sciences Ltd. was founded in 2014 and is based in London, United Kingdom.
Commentary & Analysis
What You Need to Know About Roivant Sciences Ltd.'s Q1 Earnings
Roivant Sciences Ltd.'s fiscal Q1 earnings report was released on Wednesday, May 20. Let's dive in to see if (ROIV) missed or beat analyst's expectations.Rosalio Madrigal
Why Roivant Sciences Ltd.’s (ROIV) Stock Is Up 14.50%
As of Wednesday, May 20, Roivant Sciences Ltd.’s ROIV share price has surged by 14.50%, which has investors questioning if this is right time to sell.Tudor Pop
Why Roivant Sciences Ltd.’s (ROIV) Stock Is Up 6.21%
As of Wednesday, March 04, Roivant Sciences Ltd.’s ROIV share price has surged by 6.21%, which has investors questioning if this is right time to sell.Jenna Brashear
Why Roivant Sciences Ltd.’s (ROIV) Stock Is Up 17.48%
As of Friday, February 06, Roivant Sciences Ltd.’s ROIV share price has surged by 17.48%, which has investors questioning if this is right time to sell.Jenna Brashear
Financial Summary
| Share Statistics | ROIV | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $24,390.5 | $252.6 | 88% |
|
| Shares Out (Mil) | 812.3 | 52.3 | 93% |
|
| Institutional Ownership | 78.0% | 92.1% | 48% |
|
| Float (Mil) | 565.8 | 40.2 | 87% |
|
| Beta | 1.14 | 0.95 | 67% |
|
| Avg Daily Volume (000s) | 4,588 | 455 | 92% |
|
| Price Change (52-week) |
197.5% | 52.9% | 97% |
|
| Growth | ROIV | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | (19.0%) | 13.6% | 3% |
|
| Net Income (5yr) | 18.0% | (9.9%) | 69% |
|
| EPS (5yr) | 15.8% | 16.0% | 59 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (56.4%) | (15.6%) | 5% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 3 | 3 | 3 | |
| Current EPS | ($0.356) | ($1.496) | ($1.559) | |
| Month Ago EPS | ($0.356) | ($1.496) | ($1.559) | |
| # Rev Up | 0 | 0 | 0 | |
| # Rev Down | 1 | 0 | 1 | |
| Three Months Ago EPS | ($0.333) | ($1.159) | ($1.296) | |
| Year/Year Chg | (227.1%) | 176.0% | (40.4%) | |
| Financials | ROIV | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $8 | $38 | 8% |
|
| Net Income (TTM) (Mil) | ($300) | ($43) | 5% |
|
| EPS (TTM) | ($0.432) | ($1.600) | 28% |
|
| Operating Cash Flow (TTM) (Mil) | ($750) | ($31) | 2% |
|
| Net Cash Flow (TTM) (Mil) | ($1,295) | $5 | 3% |
|
| Long-Term Debt (Q1) (Mil) | $96 | $5 | 44% |
|
| Enterprise Value (Q1) (Mil) | $18,792 | $180 | 82% |
|
| Valuation | ROIV | Industry Median |
Percentile (All Stocks) |
|
| P/B | 5.40 | 2.56 | 80% |
|
| P/E | na | 19.0 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 0.9 | na |
|
| Ratios | ROIV | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 63.8% | na |
|
| Net Margin | na | (67.3%) | na |
|
| ROA | (5.4%) | (49.8%) | 29% |
|
| ROE | (6.5%) | (55.5%) | 30% |
|
| Liabilities to Assets | 7.3% | 30.3% | 4% |
|
| F-Score | 1 | 3 | 1% |
|
Roivant Sciences Ltd. did not pass any screens on 7/31/2026.
